Summit Global Investments Buys New Position in Novartis AG (NVS)

Summit Global Investments acquired a new position in shares of Novartis AG (NYSE:NVS) during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 6,570 shares of the company’s stock, valued at approximately $488,000.

Other large investors also recently modified their holdings of the company. Parnassus Investments CA increased its stake in shares of Novartis AG by 89.4% in the first quarter. Parnassus Investments CA now owns 8,173,974 shares of the company’s stock worth $593,720,000 after buying an additional 3,858,632 shares during the last quarter. BlackRock Inc. bought a new stake in shares of Novartis AG during the first quarter worth $210,378,000. Janus Capital Management LLC increased its stake in shares of Novartis AG by 34,406.2% in the first quarter. Janus Capital Management LLC now owns 1,759,816 shares of the company’s stock worth $130,696,000 after buying an additional 1,754,716 shares during the last quarter. Wells Fargo & Company MN increased its stake in shares of Novartis AG by 12.2% in the first quarter. Wells Fargo & Company MN now owns 9,100,801 shares of the company’s stock worth $675,917,000 after buying an additional 988,301 shares during the last quarter. Finally, Karp Capital Management Corp bought a new stake in shares of Novartis AG during the first quarter worth $51,745,000. 11.16% of the stock is currently owned by institutional investors.

Shares of Novartis AG (NYSE:NVS) traded down 0.50% on Friday, reaching $82.76. The company had a trading volume of 1,319,136 shares. The firm has a market capitalization of $193.90 billion, a P/E ratio of 30.22 and a beta of 0.73. The company’s 50-day moving average price is $83.92 and its 200 day moving average price is $79.10. Novartis AG has a 52 week low of $66.93 and a 52 week high of $86.90.

Novartis AG (NYSE:NVS) last posted its quarterly earnings data on Tuesday, July 18th. The company reported $1.22 earnings per share for the quarter, topping analysts’ consensus estimates of $1.16 by $0.06. Novartis AG had a return on equity of 15.51% and a net margin of 13.52%. The company had revenue of $12.24 billion during the quarter, compared to analysts’ expectations of $12.20 billion. During the same period last year, the firm earned $1.23 EPS. The firm’s revenue for the quarter was down 1.8% on a year-over-year basis. On average, analysts expect that Novartis AG will post $4.73 EPS for the current year.

ILLEGAL ACTIVITY WARNING: This piece of content was published by Community Financial News and is the sole property of of Community Financial News. If you are accessing this piece of content on another site, it was illegally copied and reposted in violation of US & international copyright & trademark laws. The correct version of this piece of content can be viewed at https://www.com-unik.info/2017/08/19/summit-global-investments-acquires-new-position-in-novartis-ag-nvs-updated-updated-updated.html.

A number of equities research analysts recently weighed in on NVS shares. Zacks Investment Research downgraded Novartis AG from a “hold” rating to a “sell” rating in a research report on Monday, July 10th. Credit Suisse Group downgraded Novartis AG from a “neutral” rating to an “underperform” rating and set a $82.25 price objective on the stock. in a research report on Wednesday, July 5th. Morgan Stanley raised Novartis AG from an “underweight” rating to an “overweight” rating in a research report on Wednesday, July 26th. Leerink Swann reissued a “market perform” rating and issued a $83.00 price target on shares of Novartis AG in a report on Thursday, June 22nd. Finally, Vetr downgraded Novartis AG from a “buy” rating to a “hold” rating and set a $78.32 price target for the company. in a report on Tuesday, April 25th. Three investment analysts have rated the stock with a sell rating, ten have issued a hold rating and six have assigned a buy rating to the stock. The company has an average rating of “Hold” and a consensus price target of $83.56.

In related news, major shareholder Bioventures Ltd Novartis acquired 266,667 shares of the firm’s stock in a transaction on Wednesday, July 5th. The stock was bought at an average cost of $15.00 per share, with a total value of $4,000,005.00. The acquisition was disclosed in a document filed with the SEC, which is available at the SEC website. 0.01% of the stock is currently owned by company insiders.

About Novartis AG

Novartis AG is a holding company, which provides healthcare solutions. The Company is engaged in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals. The Company’s segments include Innovative Medicines, Sandoz, Alcon and Corporate activities.

Institutional Ownership by Quarter for Novartis AG (NYSE:NVS)

What are top analysts saying about Novartis AG? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Novartis AG and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit